Tags

Type your tag names separated by a space and hit enter

Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
J Eur Acad Dermatol Venereol. 2008 Feb; 22(2):195-203.JE

Abstract

BACKGROUND

Pimecrolimus cream 1% has been shown to effectively control atopic eczema (AE) when applied twice daily from the first signs or symptoms of AE until clearance. Moreover, pimecrolimus cream 1% has a favourable safety profile, lacking topical corticosteroid-related side-effects such as skin atrophy, making it particularly useful to treat delicate body regions (e.g. the face).

OBJECTIVE

The objective of this naturalistic study was to monitor the safety, tolerability and efficacy of pimecrolimus when used in the long-term management of AE in a real-life setting.

METHODS

A multicentre, open-label study was conducted in 2034 patients aged >or= 3 months with mild to moderate AE for up to 12 months' duration. Patients applied pimecrolimus cream twice daily, initiating treatment at first signs or symptoms of AE, continuing until clearance.

RESULTS

Patients (n= 1847; 91%) completed 3 months of the study. Treatment success (clear or almost clear AE) after 3 months of treatment was observed on the whole body in 59% of patients and on the face in 81% of patients. Disease improvement of whole body and face was seen in 77% and 63% of patients, respectively. Pruritus was absent or mild in 79% of patients. Pimecrolimus cream was well tolerated throughout the study.

CONCLUSION

In a daily practice setting, pimecrolimus cream 1% effectively and safely controls AE.

Authors+Show Affiliations

Division of Environmental Dermatology and Allergology GSF/TUM, Department of Dermatology and Allergy Biederstein, Technical University, Munich, Germany. johannes.ring@lrz.tum.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18211413

Citation

Ring, J, et al. "Control of Atopic Eczema With Pimecrolimus Cream 1% Under Daily Practice Conditions: Results of a > 2000 Patient Study." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 22, no. 2, 2008, pp. 195-203.
Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. J Eur Acad Dermatol Venereol. 2008;22(2):195-203.
Ring, J., Abraham, A., de Cuyper, C., Kim, K., Langeland, T., Parra, V., Pigatto, P., Reunala, T., Szczepanski, R., Möhrenschlager, M., Bräutigam, M., Rossi, A. B., Meents-Kopecky, E., & Schneider, D. (2008). Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. Journal of the European Academy of Dermatology and Venereology : JEADV, 22(2), 195-203. https://doi.org/10.1111/j.1468-3083.2007.02368.x
Ring J, et al. Control of Atopic Eczema With Pimecrolimus Cream 1% Under Daily Practice Conditions: Results of a > 2000 Patient Study. J Eur Acad Dermatol Venereol. 2008;22(2):195-203. PubMed PMID: 18211413.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. AU - Ring,J, AU - Abraham,A, AU - de Cuyper,C, AU - Kim,K, AU - Langeland,T, AU - Parra,V, AU - Pigatto,P, AU - Reunala,T, AU - Szczepanski,R, AU - Möhrenschlager,M, AU - Bräutigam,M, AU - Rossi,A B, AU - Meents-Kopecky,E, AU - Schneider,D, PY - 2008/1/24/pubmed PY - 2008/3/28/medline PY - 2008/1/24/entrez SP - 195 EP - 203 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 22 IS - 2 N2 - BACKGROUND: Pimecrolimus cream 1% has been shown to effectively control atopic eczema (AE) when applied twice daily from the first signs or symptoms of AE until clearance. Moreover, pimecrolimus cream 1% has a favourable safety profile, lacking topical corticosteroid-related side-effects such as skin atrophy, making it particularly useful to treat delicate body regions (e.g. the face). OBJECTIVE: The objective of this naturalistic study was to monitor the safety, tolerability and efficacy of pimecrolimus when used in the long-term management of AE in a real-life setting. METHODS: A multicentre, open-label study was conducted in 2034 patients aged >or= 3 months with mild to moderate AE for up to 12 months' duration. Patients applied pimecrolimus cream twice daily, initiating treatment at first signs or symptoms of AE, continuing until clearance. RESULTS: Patients (n= 1847; 91%) completed 3 months of the study. Treatment success (clear or almost clear AE) after 3 months of treatment was observed on the whole body in 59% of patients and on the face in 81% of patients. Disease improvement of whole body and face was seen in 77% and 63% of patients, respectively. Pruritus was absent or mild in 79% of patients. Pimecrolimus cream was well tolerated throughout the study. CONCLUSION: In a daily practice setting, pimecrolimus cream 1% effectively and safely controls AE. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/18211413/Control_of_atopic_eczema_with_pimecrolimus_cream_1_under_daily_practice_conditions:_results_of_a_>_2000_patient_study_ L2 - https://doi.org/10.1111/j.1468-3083.2007.02368.x DB - PRIME DP - Unbound Medicine ER -